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Rheumatoid arthritisThis study evaluated the hypothesis that neutral (APN) and dipeptidyl-IV (DPPIV) aminopeptidase activity
levels would be critical for the susceptibility to arthritis in collagen-induced model (CIA). The macroscopic
signs of arthritis in CIA rats were checked and peripheral blood, synovial ﬂuid and synovial tissue from
knee joint were withdrawn. Soluble (SF) and solubilized membrane-bound (MF) fractions from the synovial
tissue and peripheral blood mononuclear cells (PBMCs) were obtained. APN and DPPIV activities were ﬂuor-
ometrically quantiﬁed. Severe swelling in both the entire hind paws was the minimum criterion to select CIA
rats with arthritis. These arthritic rats had high APN in plasma, synovial ﬂuid and SF of the synovial tissue,
together with low APN and DPPIV in MF of PBMCs and hallmark histological changes in tibio-tarsal joint.
CIA rats with no macroscopic signs of arthritis were diagnosed as resistant and they had low APN in MF of
the synovial tissue, low DPPIV in SF of PBMCs and high DPPIV in plasma together with histological aspects
of tibio-tarsal joint similar to healthy control rats. Data suggested that APN and DPPIV activity levels are re-
lated to the development of arthritis, being protective or inducer of the susceptibility. Understanding what is
controlling the compartment-speciﬁc changes of these peptidases and looking at ways in which to manipu-
late their activities may lead to a better knowledge of the arthritic processes and novel treatments.se; APN, neutral aminopepti-
IA, collagen-induced arthritis;
; LDH, lactate dehydrogenase;
denine dinucleotide, reduced
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Collagen-induced arthritis (CIA) is a T cell-dependent animal
model of autoimmunity in which susceptibility has been associated
with genes expressed at different stages of the disease within and
outside the major histocompatibility complex (MHC), and CIA has
been studied extensively because of its similarities to human rheu-
matoid arthritis (RA) [1–4]. While the direct role of T cells in the
pathogenesis of CIA is unclear, the B cell immunoglobulin response
to collagen type II (CII) is critical to the development of CIA, and
also the transgenic expression of certain molecules associated with
susceptibility to RA such as HLA-DR1 (*0101) or DR4 (*0401) is
known to confer susceptibility to CIA [5]. Despite advances, addi-
tional unidentiﬁed molecular susceptibility factors must be associat-
ed with increased predisposition to develop RA. Standard diagnosis,
prognosis and therapy for RA still have also numerous limitations.
Heterogeneous cellular pathways and biochemical mechanisms areresponsible for generating the glycoprotein complexes of peptide
and MHC that are displayed on the surfaces of antigen-presenting
cells for recognition by T lymphocytes [6]. Recently, the glycopep-
tide CII259–273, a fragment from CII, was shown to induce tolerance
in mice susceptible to CIA, opening a new perspective to the devel-
opment of an altered glycopeptide for inducing immunological tol-
erance in CIA and a possible way for a therapeutic vaccine for the
treatment of RA [7]. Furthermore, changes in proteins implicated
in matrix degradation, cell activation, inﬂammation and bone colla-
gen degradation products accompany early knee and osteoarthritis
development and can precede radiographic detection by several
years [8].
Aminopeptidase (AP) enzymes are ubiquitous exopeptidases that
catalyze the removal of one or more N-terminal residues from target
proteins, peptides and amide or arylamide derivative of amino acids
[9]. The functions of these enzymes in RA are controversial and poorly
understood, though they have been shown to participate in the cleav-
age of antigenic peptides in endoplasmic reticulum, and in so doing
either create or destroy MHC class I-presented epitopes [10], as well
as in mediator generation and associated inﬂammation [11–17]. Re-
cently, basic AP (APB) activity was correlated with susceptibility to
develop edema and high levels of serum TNF-alpha in a rat CIA
model [18]. Among other AP enzymatic activities that have been
also consistently associated with inﬂammatory and immune process-
es the most outstanding are neutral AP (APN) and dipeptidyl pepti-
dase IV (DPPIV) [11–17,19–20].
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characterized by altered activity levels of APN and DPPIV, they were
quantiﬁed in the synovial ﬂuid, blood plasma and soluble (SF) and
solubilized membrane-bound (MF) fractions from the synovial tissue
of the knee and from peripheral blood mononuclear cells (PBMCs) of
control and CII-treated rats which developed or not arthritis.
2. Materials and methods
2.1. Animals and treatments
Sixty-six adult male Wistar rats, weighing 150–160 g, were main-
tained in polyethylene cages (inside length×width×height=56×
35×19 cm) with food and tap water ad libitum, in a container with
controlled temperature (25 °C), relative humidity (65.3±0.9%) and
12 h:12 h photoperiod light:dark (lights on at 6:00 am). The animals
and research protocols used in this study are in agreement with
the COBEA (Brazilian College of Animal Experimentation) and were
approved by the Ethics Committee of the Instituto Butantan
(432/07). The animals were anesthetized with a solution of ketamine
(Syntec, Brazil) (3.75%) and xylazine (Calmiun) (Agener Union,
Brazil) (0.5%) at a dose of 0.2 mL/100 g body weight, via intraperito-
neal, and then subjected to induction of arthritis as previously
described by Mendes et al. [18]. Brieﬂy, CII from chicken (Sigma,
USA) dissolved in 0.01 M acetic acid and emulsiﬁed in an equal
volume of Freund's incomplete adjuvant (Sigma, USA) (prepared at
4 °C just before use), was administered via a single intradermal dose
of 0.4 mg/0.2 mL/animal, into the proximal one-third of the tail
(induced animals, n=50), or with 0.9% saline at the same scheme
of administration (sham induction, n=16). On day 41 after induc-
tion, signiﬁcant changes in redness and/or swelling were macroscop-
ically undetected in 30% or evident in 70% of rats. The rats with no
macroscopic signs of arthritis were grouped as resistant to induction
of CIA (n=15). Severe swelling in both the entire hind paws was ob-
served in 60% of rats, which were grouped as arthritic animals
(n=30). All the rats in intermediate level of swelling (10%) were
not included in the present study. At this same day, after anesthesia
using the same scheme speciﬁed above, the hind paw swelling was
quantiﬁed by macroscopic measurement of the dorsal-plantar thick-
ness in the region of the metatarsus with a micrometer (Mitutoyo,
USA). Both paws were measured and calculated the average thickness
of each animal. Joint pathology was examined by histology.
2.2. Obtaining samples
The blood was withdrawn from the left ventricle with heparinized
syringes and centrifuged at 200×g for 10 min at room temperature to
separate plasma (supernatant) from the pellet containing PBMCs and
other blood cells. As previously described by Mendes et al. [18], syno-
vial ﬂuid and synovial tissue were subsequently removed from both
knees of each animal. The withdrawal of synovial ﬂuid and synovial
tissue was performed as follows: joint cavity was opened, the patellar
ligament was carefully removed and then 200 μL of 0.9% NaCl was
injected intraarticularly into each knee. Subsequently, the synovial
ﬂuid was aspirated with the same syringe. After this aspiration, the
synovial membrane was excised together with connective tissue
and infrapatellar fat pad of the joint capsule, after careful removal of
the surrounding patellar adipose tissue.
2.3. Histology
Histological analysis was performed based on the methodology
described by Hashmi et al. [21]. Brieﬂy, hind right paws were ﬁxed
in 10% formalin for a week and transferred to 70% ethanol. Decalciﬁ-
cation was performed in 5.5% EDTA solution for 60 days. The EDTA so-
lution was changed every 48 h. After decalciﬁcation, the region of thetibio-tarsal joint was separated from the rest of the paw in order to be
submitted to the preparation of histological slides. Dehydration was
performed with increasing concentrations of ethanol (70%, 95%, 95%,
100%, 100% and 100%). Then, ethanol was replaced by xylene in
three consecutive baths. In turn, the xylene was replaced with paraf-
ﬁn at 60 °C in three consecutive baths. Then, the samples were em-
bedded in parafﬁn melted. The cuts were made longitudinally in the
thickness of 5 μm, for mounting the slides. The slides were stained
with hematoxylin–eosin (HE). The analysis was performed under a
light microscope Nikon E600 equipped with a digital camera Cool-
SNAP-PRO®, using the Image-Pro Plus® 4.0 software (Cybernetics).2.4. Separation and counting of PBMCs
It was performed according to the methodology adapted from
Böyum [22] and Tamura et al. [23] as follows. The pellet resulting
from the obtainment of blood plasma was reconstituted to the origi-
nal volume with 0.9% NaCl and then carefully layered on an equal vol-
ume of Percoll (ρ=1.077 mg/mL) (GE-Healthcare, USA) and
subsequently centrifuged (200×g for 20 min at room temperature).
The layer containing the PBMCs was then removed from the tube
and washed twice with 0.9% NaCl (1:3 v/v diluted blood cells) and
centrifuged again at the same conditions to discard the supernatant.
PBMCs were resuspended in 0.5 mL of 0.9% NaCl and the total number
of PBMCs was assessed in 20 μL aliquots of this suspension diluted
with Turk's ﬂuid (1:20, v/v). Cell counting was performed in a Neu-
bauer chamber under optical microscopy.2.5. Fractionation of the synovial tissue and PBMCs
As previously described by Mendes et al. [18], the synovial tissue
from both knees of each animal was homogenized in 10 mM Tris–
HCl buffer, pH 7.4 (0.1 g tissue/3.0 mL) for 3 min at 15,000 rpm
(homogenizer Polytron-Aggregate, Kinematica, Switzerland).
PBMCs, resuspended in 0.9% NaCl, were sonicated in 10 mM Tris–
HCl, pH 7.4 (3.0×106 cells/mL), for 10 s at amplitude level of
40 μm at a constant frequency of 20 kHz. These samples were then
ultracentrifuged at 100,000×g for 35 min (ultracentrifuge Hitachi
CP60E). The resulting supernatants correspond to SF. The resulting
pellets were washed twice with the same buffer and ultracentri-
fuged at 100,000×g for 35 min, to assure the complet removal of
SF. The pellet was homogenized for 3 min at 800 rpm (homogenizer
Tecnal TE 099) with the same volume of the same buffer plus Triton
X-100 (0.1%) and ultracentrifuged again (100,000×g for 35 min).
The resulting supernatants correspond to MF. All procedures were
carried out at 4 °C.
As a marker for the synovial tissue and PBMCs fractionation proce-
dure, lactate dehydrogenase (LDH) activity was determined, photo-
metrically, at 340 nm, in triplicates of individual samples of SF and
MF, as previously described [24]. LDH activity was obtained by sub-
tracting the values of the second from that of the ﬁrst reading, and ex-
trapolated by comparison with a standard curve of NADH.2.6. Total protein
Total protein was measured photometrically (Power Wave XR
spectrophotometer, Bio-Tek, USA), at 630 nm, in triplicates of individ-
ual samples of 40 μL of synovial ﬂuid, plasma (diluted 500-fold) and
SF (diluted 10-fold) and MF (diluted 2-fold) from the synovial tissue
and PBMCs, by the method of Bradford [25], using a Bio-Rad protein
assay reagent (Hercules, USA). Protein contents were extrapolated
by comparison with standard curves of bovine serum albumin (BSA)
in the same diluent.
Fig. 1. Lactate dehydrogenase (LDH) activity in soluble fraction (SF) and solubilizedmem-
brane-bound fraction (MF) from synovial tissue of sham induced (control) (A) and CII-
treated that developed hind paw edema (arthritic) (B). Values are means±SEM. Number
of animals in parentheses over the bars. *pb0.0001, unpaired two-tailed Student's t test.
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AP activities were measured on the basis of the amount of
β-naphthylamine (Sigma, USA) (for APN) [24] or 4-methoxy-β-
naphthylamine (Sigma, USA) (for DPPIV) [26] released as a result
of the enzyme activity in triplicates of individual samples incubated
at 37 °C, for 30 min, in 96-well ﬂat bottommicroplates (Corning Inc.,
USA) with prewarmed substrate solution diluted to 0.125 mM for
APN or 0.2 mM for DPPIV in respective 0.05 M buffers containing
0.1 mg BSA/mL, in a ﬁnal volume of 300 μL. For APN activity 25 μL
blood plasma (200 to 450 μg protein), 10 μL synovial ﬂuid (5 to
20 μg protein), 10 μL SF (1.3 to 7.7 μg protein) and 25 μL MF (2.6 to
15 μg protein) from the synovial tissue, and 50 μL SF (22 to 72 μg pro-
tein) and 100 μL MF (13 to 44 μg protein) from PBMCs were incubat-
ed with L-alanine-β-naphthylamide (Sigma, USA) in phosphate
buffer, pH 7.4, with 1 mM DL-dithiothreitol (Sigma, USA) (Sigma,
USA). For DPPIV activity 25 μL blood plasma (51 to 112 μg protein),
10 μL synovial ﬂuid (5 to 20 μg protein), 25 μL SF (2.8 to 20 μg pro-
tein) and MF (2.6 to 15 μg protein) from the synovial tissue, and 50 μL
SF (22 to 72 μg protein) and 100 μL MF (13 to 44 μg protein) from
PBMCs were incubated with H-Gly-Pro-4-methoxy-β-naphthylamide
(Peninsula, USA) in Tris/HCl buffer, pH 8.3. β-Naphthylamine or
methoxy-β-naphthylamine was estimated ﬂuorometrically (FL600FA
Microplate Fluorescence/Absorbance Reader Bio-Tek, USA), at
460/40 nmemissionwavelength and 360/40 nmexcitationwavelength.
The value of incubates at zero time (blank) was subtracted and the rel-
ative ﬂuorescence was converted to picomoles of β-naphthylamine or
methoxy-β-naphthylamine by comparison with a correspondent stan-
dard curve. Enzyme activities were expressed as picomoles of hydro-
lysed substrate min−1mg protein−1.
2.8. Statistical analysis
Data are shown as mean±standard error of the mean (SEM) and
were analyzed statistically using the GraphPad Instat™ software
package. Regression analyses were performed to obtain standard
curves of protein, NADH, β-naphthylamine and methoxy-β-
naphthylamine. Student's t-test was performed to compare values
of LDH between SF and MF. One-way analysis of variance (ANOVA)
followed, when differences were detected, by the Tukey–Kramer
multiple comparison test was performed to compare values among
control, arthritic and resistant groups. In all the calculations a mini-
mum critical level of pb0.05 was set.
3. Results
Fig. 1 shows that LDH activity in SF was higher than in MF of syno-
vial tissue in control and CIA animals with arthritis. The same pattern
was observed in resistant CIA animals. Qualitatively similar results
were obtained in SF and MF from PBMCs of all groups (data not
shown).
All selected arthritic animals had dorsal-plantar thickness N7 mm
in the region of the metatarsus of both hind paws, and all selected re-
sistant animals had this thickness similar to control. There is no evi-
dence of histological changes of articular cartilage and subchondral
bone in control (Fig. 2I) and resistant (Fig. 2III) animal groups. How-
ever, in arthritic group (Fig. 2II) there is erosion in the cartilage and
bone tissues, presence of pannus into intraarticular cavity and inﬁl-
tration of cells.
Fig. 3 shows that APN activity is highly expressed in MF from the
synovial tissue of all animal groups under study. In SF from the syno-
vial tissue, APN activity was higher in arthritic than in control or resis-
tant (Fig. 3A). Resistant and control animals had similar APN activity
in SF from the synovial tissue (Fig. 3A). In MF from the synovial tissue
APN activity was lower in resistant than in control or arthritic
(Fig. 3B). Control and arthritic animals had similar APN activity inMF from the synovial tissue (Fig. 3B). Arthritic had higher APN activ-
ity than control or resistant animals in synovial ﬂuid (Fig. 3C) and
blood plasma (Fig. 3D). Resistant and control animals had similar
APN activity in synovial ﬂuid (Fig. 3C) and blood plasma (Fig. 3D).
Fig. 4 shows that APN activity is highly expressed in SF from
PBMCs of all groups under study. APN activity in all groups under
study was similar in SF from PBMCs (Fig. 4A). However, arthritic
had lower APN activity than control or resistant animals in MF from
PBMCs (Fig. 4B). Resistant and control animals had similar APN activ-
ity in MF from PBMCs (Fig. 4B).
DPPIV activity in all animal groups under study was similar in
blood plasma (Fig. 5D) and SF (Fig. 5A) and MF (Fig. 5B) from synovi-
al tissue, being relatively expressed at lower levels in synovial ﬂuid
(Fig. 5C). Arthritic, resistant and control animals had similar DPPIV
activity in synovial ﬂuid (Fig. 5C) and SF (Fig. 5A) and MF (Fig. 5B)
of synovial tissue. In blood plasma, DPPIV activity was higher in resis-
tant than in control or arthritic (Fig. 5D). Control and arthritic animals
had similar DPPIV activity in blood plasma (Fig. 5D).
Fig. 6 shows that DPPIV activity is highly expressed in MF from
PBMCs of all groups under study. Resistant animals had similar
DPPIV activity than control, but lower than arthritic animals in SF of
PBMCs (Fig. 6A), while arthritic had lower DPPIV activity than control
or resistant in MF from PBMCs (Fig. 6B). Resistant and control animals
had similar DPPIV activity in MF from PBMCs (Fig. 6B).
4. Discussion
As preconized by Mendes et al. [18], arthritis and resistance in CIA
model can be initially evidenced macroscopically according to the
presence of severe swelling in both the entire hind paws (arthritic),
and total absence of changes in redness and/or swelling (resistant),
both conditions which were conﬁrmed here by correspondent typical
histological aspects of the tibio-tarsal joint. Based on the macroscopic
grading scale proposed by Erlandsson Harris et al. [27], all the arthrit-
ic animals selected in the present study had the maximum score.
LDH activity is well known as a cytosolic marker [9, 13–15, 18, 24,
27, 28] and its higher activity in SF in comparison with MF from the
Fig. 2. Histology of the tibio-tarsal joint in longitudinal section. I (control animals) and III (animals resistant to induction of arthritis): the cartilage (C) and bone (O) are presented
without histopathological changes and no cellular inﬁltration exists into the intraarticular cavity (CA). II (arthritic animals): the synovium is hyperplastic with pannus (P), invasion
of CA and erosion of C and O. HE.
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procedure. Thus, the present study is the ﬁrst one to analyze APN
and DPPIV activities in these separate fractions from the synovial tis-
sue and PBMCs.
The hydrolytic ability of murine macrophages on six different
naphthylamide derivative substrates for AP enzymes revealed a rise
in activity levels of APN and DPPIV when these cells are elicited by
thioglycolate [13]. The effects of modifying antirheumatic drugs,
such as methotrexate and cyclosporine [19] have also been associated
to altered levels of APN and DPPIV activities [14–15]. APN and DPPIV
enzymatic activities are thought to be exhibited by various isozymes,
including soluble forms in serum or plasma [29]. Little systematic
data was available on the role of APN and DPPIV enzymatic activities
in RA and none related to predisposition to develop RA. The present
study shows that APN and DPPIV activities are expressed in synovial
ﬂuid, plasma and SF and MF from synovial tissue and PBMCs of con-
trol, arthritic and resistant animals. The present study mainly shows
that resistant animals have higher DPPIV activity in plasma and
lower DPPIV activity in SF from PBMCs together with lower APN ac-
tivity in MF from the synovial tissue when compared with control
or arthritic animals. In addition, APN activity is higher in the synovialﬂuid, plasma and SF from synovial tissue and lower in MF from PBMCs
of arthritic animals when compared with control or resistant.
APN has been reported as an activation-associated molecule of T
lymphocytes from the synovial ﬂuid and the peripheral blood from
patients suffering from RA or juvenile idiopathic arthritis [11]. In
this sense, APNwas supposed to participate in the mechanism of lym-
phocyte involvement in inﬂamed joints of RA patients as a lympho-
cyte chemoattractant [12]. In acute neutrophil driven inﬂammation,
the neutrophil chemoattractant Pro-Gly-Pro (PGP), a biomarker for
chronic obstructive pulmonary disease, is degraded by AP activity of
leukotriene A4-hydrolase, which facilitates the resolution of inﬂam-
mation, but in chronic situation the inhibition of this AP activity
could lead to the accumulation of the chemoattractant and neutro-
phils [17]. APN is also being related to extracellular matrix degrada-
tion, antigen processing [30], T cell chemotaxis [12], motility and
cellular adhesion during angiogenesis [31] and metabolism of en-
kephalins [32], substance P [33] and angiotensin (Ang) III [34]. The
antinociceptive effect of enkephalins is well known [32] and sub-
stance P, a regulatory peptide, has effects on inﬂammation, modulat-
ing vascular tone and permeability, immune cell function and cellular
proliferation [33]. Moreover, the hydrolyses of Ang III by APN and APB
Fig. 3. APN activity of soluble (SF) (A) and solubilized membrane-bound (MF) (B) fractions from synovial tissue, synovial ﬂuid (C) and blood plasma (D) in sham induced (control),
CII-treated that developed arthritis and CII-treated rats that did not develop arthritis (resistant). Values are means±SEM. Number of animals in parentheses over the bars. Analysis
of variance ANOVA (A, pb0.0001; B, pb0.002; C and D, pb0.0001) with post-hoc Tukey–Kramer multiple comparisons test; *pb0.05 vs other two groups in the same panel.
Fig. 4. APN activity of soluble (SF) (A) and solubilized membrane-bound (MF) (B) frac-
tions from PBMCs in sham induced (control), CII-treated that developed arthritis and
CII-treated rats that did not develop arthritis (resistant). Values are means±SEM.
Number of animals in parentheses over the bars. Analysis of variance ANOVA
(A, p=0.1610; B, pb0.044) with post-hoc Tukey–Kramer multiple comparisons test;
*pb0.05 vs other two groups in the same panel.
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pathway [34]. In the present study, higher APN activity in the synovial
ﬂuid, plasma and SF from the synovial tissue, as well as lower APN ac-
tivity in MF from PBMCs of arthritic animals reinforce the hypothesis
that, in addition to APB activity [18], changes on APN activity are re-
lated to pro- [35] and anti-inﬂammatory [36] roles of different Ang
metabolites. Functionally, in the synovial ﬂuid, the secreted form of
APN could hydrolyze peptides such as Ang III and substance P and
stimulate the maintenance of inﬂammation in the joint. In the cytosol,
the increase of APN activity could also contribute to the proteolysis
for the processing of MHC I ligands [37–38]. It is known that cytosolic
peptides may bind to MHC II molecules for presentation to CD4+
cells [39]. Immunohistochemical studies have shown an increased
APN in cellular membrane of synovial ﬁbroblasts [12] and in the cel-
lular membrane of synovial vessels [33] of patients with RA. Also by
immunohistochemistry, it was observed an increase of APN/CD13 in
synoviocytes [40] and in synovial tissue [41] of patients with RA.
However, the detection of APN by immunohistochemistry is not
enough to demonstrate its enzymatic activity [42]. In the present
study, it was observed a decrease of APN activity in MF from the syno-
vial tissue of animals resistant to CIA and from PBMCs of arthritic an-
imals. This data suggests that the mechanism involved in reducing
APN activity in the resistance to arthritis in CIA model might be oppo-
site of the mechanism related to the increase of cytosolic APN in the
synovial tissue and in MF from PBMCs, which characterize the devel-
opment of the disease together with the decrease of DPPIV inMF from
PBMCs. Probably, the mechanism could be related to APN-mediated
plasma membrane instability, altering intracellular functions of this
enzyme. The decrease of APN activity in MF from synovial tissue
and the increase of DPPIV activity in plasma and the decrease of
DPPIV in SF from PBMCs relative to control subjects can be an attrac-
tive tool for estimation of the susceptibility to develop RA. Therefore,
based on current data and on the results presented here, it is probable
that APN activity participates in peptide processing and chemotaxis
Fig. 5. DPPIV activity of soluble (SF) (A) and solubilized membrane-bound (MF) (B) fractions from synovial tissue, synovial ﬂuid (C) and blood plasma (D) in sham induced (control),
CII-treated that developed arthritis and CII-treated rats that did not develop arthritis (resistant). Values aremeans±SEM. Number of animals in parentheses over the bars. Analysis of
variance ANOVA (A, p=0.2808; B, p=0.3504; C, p=0.3039; D, pb0.0014) with post-hoc Tukey–Kramer multiple comparisons test; *pb0.05 vs other two groups in the same panel.
Fig. 6. DPPIV activity of soluble (SF) (A) and solubilized membrane-bound (MF)
(B) fractions from PBMCs in sham induced (control), CII-treated that developed arthri-
tis and CII-treated rats that did not develop arthritis (resistant). Values are means±
SEM. Number of animals in parentheses over the bars. Analysis of variance ANOVA
(A, pb0.012; B, pb0.0015) with post-hoc Tukey–Kramer multiple comparisons test;
*pb0.05 vs arthritic in panel A; *pb0.05 vs other two groups in panel B.
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membrane-bound factor related to the resistance to RA development.
DPPIV is known to be involved in the catabolism of chemokines,
cytokines, substance P and other peptides [33, 43]. Moreover, DPPIV
modulates lymphocyte immune responses [44]. Current data about
DPPIV activity in RA are widely divergent. As reported by Sedo et al.
[43], there is a signiﬁcant decrease of DPPIV activity in synovial ﬂuid
in RA patients compared to healthy and osteoarthritic patients,
which occurs together with an increased expression of DPPIV in
membrane and decreased activity in plasma. According to Busso et
al. [44], DPPIV in plasma is also decreased in arthritic mice. However,
Suh et al. [45] reported no differences of DPPIV activity in plasma be-
tween control and arthritic animals. Mantle et al. [46] also described
no alterations of DPPIV activity in plasma between healthy and RA pa-
tients. It has been proposed that DPPIV may have a dual role on RA
and levels of DPPIV are associated with severity of RA [44]. Soluble
DPPIV could inhibit cytokine production and membrane-bound
DPPIV could stimulate cellular response in RA [44]. Low levels of
DPPIV are related to RA severity [44], but on the other hand DPPIV in-
hibitors reduce the progression of arthritis in animal models [47]. In
the present study, DPPIV activity was altered in plasma and SF from
PBMCs of animals resistant to CIA, as well as in MF from PBMCs of ar-
thritic animals. The increase of DPPIV in plasma and its decrease in
MF from PBMCs could be related to the cleavage of circulating chemo-
kines and cytokines, which respectively would prevent (resistant) or
aggravate (arthritic) the inﬂammatory response of RA development.
The decrease found in SF from PBMCs could be related to the preva-
lence of resting state of these cells in resistant animals. Different pro-
portions of T/B cells and monocytes in PBMCs of arthritic, resistant
and normal rats may also account for some of the differences seen
in APN and DPPIV activities, mainly those in DPPIV, since it is believed
that T cells are the major source of circulating DPPIV [48, 49]. Howev-
er, the origin of DPPIV in plasma is not completely understood [48].
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is thought to be caused by circulating enzymes [50]. DPPIV is known
to be present in the cellular membrane of different cell types, includ-
ing papillary renal cell carcinoma [51]. In resting state T and NK cell
present low expression of DPPIV, which is rapidly upregulated upon
activation of these cells [49]. About 90% of circulating DPPIV activity
is shed from transmembrane CD26/DPPIV [49, 50] and the remaining
10% are related with DPPIV-like activity, such as DPPII and ﬁbroblast
activating protein (FAP)-α [49]. Therapeutic potential of DPPIV inhib-
itors has been suggested for the treatment of RA [20] and the concom-
itant inhibition of both APN and DPPIV enzyme families by means of
two separate inhibitors or by binary inhibitors with speciﬁcity for
both enzyme families was demonstrated that synergistically affects
immune cells on the level of cell cycle regulation, suppression of cer-
tain cytokines as well as the activation of regulatory T-cells [16].
Hence, the concept of a combined targeting of both families of pepti-
dases for the treatment of inﬂammatory diseases has been preconized
as a promising strategy [16].5. Concluding remarks
APN and DPPIV activities are expressed in the synovial ﬂuid, plas-
ma and SF and MF from the synovial tissue and PBMCs of rats. Rats re-
sistant to CIA are characterized by high DPPIV activity in plasma and
low in soluble fraction from PBMCs together with low APN activity
in MF from the synovial tissue. On the other hand, high APN in plas-
ma, synovial ﬂuid and SF of the synovial tissue, together with low
APN and DPPIV in MF of PBMCs characterize the susceptibility to de-
velop arthritis. Compartmentalized changes on APN and DPPIV activ-
ities represent potentially valuable new targets that may lead to a
better understanding of the arthritic processes and novel treatments.Acknowledgments
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